- Exchange: Toronto
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Valeant Pharmaceuticals International Inc
+ Add to WatchlistVRX:CN
87.7400 CAD 1.4400 1.67%
Share
As of 16:00:00 ET on 06/18/2013.
More on VRX
News for Valeant Pharmaceuticals International Inc (VRX)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Serb Galenika Says It Secures Certificate for Drug Sales in EU
- Goldman Salvages Fees With Bausch After Failed Deals
- Vanguard Touts Canadian Debt Sunk by Worst Rout Since ’08
- Valeant to Raise $7.5 Billion in Debt for Bausch & Lomb Purchase
- Serbia Extends Galenika Tender to Mid-June for Valeant Unit
- Weil, Cravath, Fried Frank, Skadden: Business of Law
- Valeant Gets Funding for Bausch Deal; RCN Cable Unit Refinances
- Valeant Agrees to Buy Bausch & Lomb in $8.7 Billion Deal
- Valeant Agrees to Buy Bausch & Lomb in $8.7 Billion Deal
- Canada Stocks Rise After Valeant Buys Bausch & Lomb
- Valeant Said to Be Near to Acquiring Bausch & Lomb
- Valeant to Borrow About $7 Billion for Bausch & Lomb Buyout
- Canadian Stocks Rise as Valeant Jump Offsets Slumps in Oil, Gold
- Kasowitz Benson, Eversheds, Latham: Business of Law
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Valeant Pharmaceuticals Announces Public Offering Of Common Shares Published Jun 17, 2013
- Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus Published Jun 07, 2013
- Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America Published Jun 05, 2013
- Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL Published Jun 03, 2013
- Ruane, Cunniff & Goldfarb Inc. Reports Holdings in Valeant Pharmaceuticals International, Inc. Published May 31, 2013
- Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole Published May 28, 2013
- Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion Published May 27, 2013
- Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer Published May 23, 2013
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease Published May 23, 2013
- A first in Quebec: Valeant officially inaugurates its international headquarters in Laval Published May 21, 2013
- Valeant Pharmaceuticals Announces 2013 Annual Meeting Results Published May 21, 2013
- /R E P E A T -- Media invitation - Inauguration of Valeant International headquarters in Laval/ Published May 21, 2013
- Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference Published May 20, 2013
- Media invitation - Inauguration of Valeant International headquarters in Laval Published May 20, 2013
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel Updated 18 minutes ago
- Medtronic’s Infuse No Better Than Bone Graft With Risk Updated 2 hours ago
- FDA Investigating Lilly’s Zyprexa Injection After Two Die Updated 2 hours ago
- Global Power Players: In The Loop (06/14)
- The Top Ten Stocks for Tuesday, June 18
- Glaxo Gets Offer for Heart Drugs With Declining Sales
- Royalty Pharma Drops Judicial Review Request of Elan Bid
- Arnold & Porter, Skadden, Cravath, Willkie: Business of Law
- Drugmakers Opened to ‘Pay for Delay’ Suits by High Court
- The Top Ten Stocks for June 17
- J&J to Buy Aragon Pharmaceuticals for Cancer Candidate
- Investor's Eyes on Bernanke: In The Loop (6/17)
- ViroPharma Shares Rise on Report of Drug Company Interest
- Elan Investors Approve Buyback to Force Royalty Bid End
- Red-Meat Eaters Increase Risk of Diabetes With More Portions
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page